Introduction to Pharmacogenomics: Role of the Histocompatibility and Immunogenetics Laboratory in Personalised Medicine-Current Status and Future Prospects.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Introduction to Pharmacogenomics: Role of the Histocompatibility and Immunogenetics Laboratory in Personalised Medicine-Current Status and Future Prospects.
Συγγραφείς:	Howell WM; Pathology Service Development, NHS Blood and Transplant, Newcastle Centre, Holland Drive, Newcastle upon Tyne, UK.
Πηγή:	International journal of immunogenetics [Int J Immunogenet] 2026 Aug; Vol. 53 (4), pp. 305-323. Date of Electronic Publication: 2026 Apr 23.
Τύπος έκδοσης:	Journal Article; Review
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Blackwell Pub Country of Publication: England NLM ID: 101232337 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-313X (Electronic) Linking ISSN: 17443121 NLM ISO Abbreviation: Int J Immunogenet Subsets: MEDLINE
Imprint Name(s):	Original Publication: Oxford, UK : Blackwell Pub., c2005-
Ιατρικοί όροι (MeSH):	Precision Medicine/methods , Pharmacogenetics/methods , Pharmacogenetics/trends , Immunogenetics/methods , Immunogenetics/trends , HLA Antigens/genetics , HLA Antigens/immunology , Histocompatibility/genetics, Neoplasms/genetics ; Neoplasms/immunology ; Neoplasms/therapy ; Immunosuppressive Agents/therapeutic use ; Histocompatibility Testing/methods ; Drug-Related Side Effects and Adverse Reactions/genetics ; Humans ; Immunotherapy
Περίληψη:	This review provides an introduction to the rapidly expanding field of pharmacogenomics and personalised medicine, with especial relevance and focus for those working in clinical Histocompatibility and Immunogenetics (H&I) laboratories supporting HLA and disease immunogenetic testing and transplantation programmes. Drug efficacy and adverse drug reactions (ADRs) are defined, and the historical background to the field is introduced, along with a current overview of established clinically actionable gene-drug interactions. HLA associations with ADRs are reviewed, including those associations already tested for in many H&I laboratories worldwide, along with a broader overview of published HLA and ADRs, to determine which-if any-associations are likely to be of clinical significance and might be added to the testing repertoire. This review is intended to inform such decision-making. In addition, pharmacogenomics as related to the transport and metabolism of immunosuppressive drugs used in clinical transplantation is considered, again with relevance to the testing repertoire of clinical H&I laboratories. Finally, the expanding role of HLA genotyping in cancer immunotherapies is discussed, along with future developments in the broader pharmacogenomics field and how H&I laboratories can contribute to this. (© 2026 John Wiley & Sons Ltd.)
References:	N Engl J Med. 2013 Oct 24;369(17):1620-8. (PMID: 24152261) Science. 1956 Sep 14;124(3220):484-5. (PMID: 13360274) Nature. 2004 Apr 1;428(6982):486. (PMID: 15057820) Nature. 2012 Jun 28;486(7404):554-8. (PMID: 22722860) Br J Clin Pharmacol. 2025 Aug;91(8):2241-2250. (PMID: 40460990) Clin Pharmacol Ther. 2016 Jan;99(1):36-7. (PMID: 26094938) Pharmgenomics Pers Med. 2012;5:63-72. (PMID: 23226063) Mol Immunol. 2014 Jan;57(1):22-7. (PMID: 23916069) Lancet Oncol. 2022 Jan;23(1):172-184. (PMID: 34895481) Mol Psychiatry. 2017 Oct;22(10):1502-1508. (PMID: 27400856) Front Immunol. 2022 Feb 18;13:863414. (PMID: 35251055) Gastroenterology. 2017 Apr;152(5):1078-1089. (PMID: 28043905) Int J Immunogenet. 2014 Feb;41(1):1-12. (PMID: 24004450) Expert Opin Drug Metab Toxicol. 2016 May;12(5):555-65. (PMID: 27010623) N Engl J Med. 2011 Mar 24;364(12):1134-43. (PMID: 21428769) Chem Res Toxicol. 2023 May 15;36(5):757-768. (PMID: 37074725) Am J Transplant. 2004 Jun;4(6):914-9. (PMID: 15147425) Br J Clin Pharmacol. 2023 Jan;89(1):390-400. (PMID: 36002314) Hum Mol Genet. 2011 Mar 1;20(5):1034-41. (PMID: 21149285) Pharmacogenet Genomics. 2009 Sep;19(9):704-9. (PMID: 19696695) Br J Clin Pharmacol. 2019 Aug;85(8):1852-1854. (PMID: 31190414) Pharm Res. 2017 Aug;34(8):1564-1569. (PMID: 28028769) Arthritis Care Res (Hoboken). 2012 Aug;64(8):1233-7. (PMID: 22422616) Sci Rep. 2015 Jul 20;5:12169. (PMID: 26190474) Curr Opin Immunol. 2013 Feb;25(1):81-9. (PMID: 23141566) Br Med Bull. 1999;55(2):366-86. (PMID: 10723863) Pharmacogenomics. 2018 Apr;19(5):495-511. (PMID: 29517418) Lancet. 2002 Mar 30;359(9312):1121-2. (PMID: 11943262) Neuropsychiatr Dis Treat. 2011;7:507-18. (PMID: 21931493) Drug Metab Pharmacokinet. 2010;25(3):298-306. (PMID: 20610889) Lancet. 2023 Feb 4;401(10374):347-356. (PMID: 36739136) J Allergy Clin Immunol. 2023 Feb;151(2):289-300.e4. (PMID: 36740326) J Allergy Clin Immunol. 2012 Jun;129(6):1562-9.e5. (PMID: 22322005) Eur J Hum Genet. 2024 Aug;32(8):903-911. (PMID: 38570725) Lancet. 2006 Aug 19;368(9536):704. (PMID: 16920476) Pharmacogenet Genomics. 2016 May;26(5):218-24. (PMID: 26959717) Pharmacogenet Genomics. 2015 Aug;25(8):402-11. (PMID: 26086150) Clin Pharmacol Ther. 2021 Feb;109(2):302-309. (PMID: 32779747) Pharmacogenomics J. 2018 May 22;18(3):480-486. (PMID: 28786423) Clin Pharmacol Ther. 2019 May;105(5):1095-1105. (PMID: 30447069) N Engl J Med. 1973 Apr 5;288(14):704-6. (PMID: 4688372) Hum Immunol. 2019 May;80(5):325-334. (PMID: 30797823) Clin Genet. 1999 Oct;56(4):247-58. (PMID: 10636440) Epilepsia. 2008 Dec;49(12):2087-91. (PMID: 18637831) BMC Med Genomics. 2025 Oct 7;18(1):151. (PMID: 41057866) Clin Pharmacol Ther. 2015 Jul;98(1):19-24. (PMID: 25801146) Hum Immunol. 2014 Aug;75(8):930-9. (PMID: 24994462) Ther Drug Monit. 2014 Dec;36(6):710-5. (PMID: 24739669) Int J Dermatol. 2022 Feb;61(2):184-190. (PMID: 34553372) Future Healthc J. 2022 Jul;9(2):174-178. (PMID: 35928194) Clin Pharmacol Ther. 2018 Apr;103(4):574-581. (PMID: 29392710) Pharmacogenomics. 2008 Nov;9(11):1617-22. (PMID: 19018717) Chem Res Toxicol. 2018 Oct 15;31(10):1022-1024. (PMID: 30179004) Lancet. 1973 Apr 28;1(7809):904-7. (PMID: 4123836) Indian J Dermatol Venereol Leprol. 2009 Nov-Dec;75(6):579-82. (PMID: 19915237) Pharmacogenet Genomics. 2017 Sep;27(9):313-322. (PMID: 28704257) Nat Cancer. 2020 Dec;1(12):1167-1175. (PMID: 35121931) Pharmacogenomics J. 2005;5(1):6-13. (PMID: 15492763) J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33229510) Br J Clin Pharmacol. 2011 Dec;72(6):948-57. (PMID: 21671989) J Clin Oncol. 2011 Feb 20;29(6):667-73. (PMID: 21245432) World Health Organ Tech Rep Ser. 1972;498:1-25. (PMID: 4625548) Diabet Med. 2016 Jun;33(6):712-7. (PMID: 26802434) Nat Biotechnol. 1997 Sep;15(9):829-30. (PMID: 9306389) Lancet. 2002 Mar 2;359(9308):727-32. (PMID: 11888582) Pharmacogenomics J. 2016 Apr;16(2):180-5. (PMID: 25987243) Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):665-673. (PMID: 29691732) Front Pharmacol. 2018 Sep 26;9:1049. (PMID: 30319405) Pharmacogenet Genomics. 2008 Feb;18(2):99-107. (PMID: 18192896) Immunol Rev. 2012 Nov;250(1):158-66. (PMID: 23046128) Clin Transplant. 2018 Aug;32(8):e13332. (PMID: 29920787) Clin Pharmacokinet. 2014 Feb;53(2):123-39. (PMID: 24249597) Allergy. 2023 Nov;78(11):2980-2993. (PMID: 37452515) Clin Transplant. 2016 Sep;30(9):1074-81. (PMID: 27314545) Seizure. 2018 Aug;60:163-171. (PMID: 30015149) Clin Pharmacol Ther. 2019 Feb;105(2):476-485. (PMID: 30270535) N Engl J Med. 2021 Sep 23;385(13):1196-1206. (PMID: 34551229) J Thorac Oncol. 2019 Jun;14(6):1021-1031. (PMID: 30780001) JAMA Oncol. 2025 Jan 1;11(1):74-76. (PMID: 39602136) Pharmacol Res. 2017 Jan;115:168-178. (PMID: 27888155) Am J Transplant. 2019 Oct;19(10):2795-2804. (PMID: 30953600) Transplantation. 2016 Oct;100(10):2129-2137. (PMID: 27653228) HLA. 2025 Oct;106(4):e70442. (PMID: 41137743) Drug Metab Pharmacokinet. 2016 Dec;31(6):467-470. (PMID: 27839692) Am J Trop Med Hyg. 2017 May;96(5):1014-1018. (PMID: 28167593) Pharmacogenomics J. 2008 Jun;8(3):186-95. (PMID: 17505501) Science. 1999 Oct 15;286(5439):487-91. (PMID: 10521338) Pharmacogenomics. 2018 Feb;19(3):175-184. (PMID: 29318894) Drugs R D. 2017 Jun;17(2):279-286. (PMID: 28229376) Front Pharmacol. 2020 Sep 23;11:567048. (PMID: 33071783) Drug Ther Bull. 2023 Jun;61(6):87-91. (PMID: 37193588) HLA. 2018 Jan;91(1):3-16. (PMID: 29171940) J Hematol Oncol. 2025 Feb 17;18(1):18. (PMID: 39962549) Front Pharmacol. 2017 Nov 29;8:879. (PMID: 29238301) Blood. 2014 Aug 21;124(8):1266-76. (PMID: 24970932) Asia Pac Allergy. 2016 Apr;6(2):77-89. (PMID: 27141480) Pediatr Transplant. 2018 Nov;22(7):e13285. (PMID: 30178515) Genet Mol Res. 2015 Nov 26;14(4):15148-57. (PMID: 26634478) Semin Liver Dis. 2014 May;34(2):123-33. (PMID: 24879978) Int J Immunogenet. 2017 Feb;44(1):7-26. (PMID: 28092143) J Allergy Clin Immunol. 2016 Oct;138(4):943-955. (PMID: 27720019) HLA. 2019 Jun;93(6):417-435. (PMID: 30895730) Clin Pharmacol Ther. 2018 Apr;103(4):599-618. (PMID: 28994452) Pharmacogenomics J. 2019 Apr;19(2):211-218. (PMID: 29298994) Eur J Hum Genet. 2024 Feb;32(2):155-162. (PMID: 36056234) Epilepsia. 2010 Dec;51(12):2461-5. (PMID: 21204807) Exp Biol Med (Maywood). 2018 Feb;243(3):291-299. (PMID: 28950720) Clin Pharmacol Ther. 2014 May;95(5):499-500. (PMID: 24561393) Blood. 2025 Sep 18;146(12):1511-1524. (PMID: 40499009) Nat Genet. 2010 Aug;42(8):711-4. (PMID: 20639878) Gastroenterology. 2011 Jul;141(1):338-47. (PMID: 21570397) Am J Transplant. 2018 Dec;18(12):2905-2913. (PMID: 29689130) Int J Immunogenet. 2026 Aug;53(4):305-323. (PMID: 42026887) Pharmacogenomics. 2020 Nov;21(17):1237-1246. (PMID: 33118435) Nat Genet. 2009 Jul;41(7):816-9. (PMID: 19483685) Nat Commun. 2014 Sep 04;5:4757. (PMID: 25187353) Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1083-1084. (PMID: 29661769) Nature. 1970 Jan 31;225(5231):461-2. (PMID: 5262706) Clin Pharmacol Ther. 2014 Apr;95(4):423-31. (PMID: 24253661) Front Pharmacol. 2021 Jan 25;11:595219. (PMID: 33568995) J Antimicrob Chemother. 2017 Apr 1;72(4):1152-1162. (PMID: 28062682) Science. 2018 Feb 2;359(6375):582-587. (PMID: 29217585) Ann Oncol. 2023 Oct;34(10):920-933. (PMID: 37704166) Aust Prescr. 2017 Jun;40(3):101-104. (PMID: 28798515) HLA. 2026 Jan;107(1):e70535. (PMID: 41503732)
Contributed Indexing:	Keywords: HLA; adverse drug reactions; cancer immunotherapy; immunosuppression
Substance Nomenclature:	0 (HLA Antigens) 0 (Immunosuppressive Agents)
Entry Date(s):	Date Created: 20260424 Date Completed: 20260710 Latest Revision: 20260813
Update Code:	20260813
PubMed Central ID:	PMC13352108
DOI:	10.1111/iji.70052
PMID:	42026887
Βάση Δεδομένων:	MEDLINE

Full Text Finder

Περιγραφή
ISSN:	1744-313X
DOI:	10.1111/iji.70052